Development and Validation of an In Silico Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients
Zaloumis SG., Whyte JM., Tarning J., Krishna S., McCaw JM., Cao P., White MT., Dini S., Fowkes FJI., Maude RJ., Kremsner P., Dondorp A., Price RN., White NJ., Simpson JA.
Most deaths from severe falciparum malaria occur within 24 h of presentation to a hospital. Intravenous (i.v.) artesunate is the first-line treatment for severe falciparum malaria, but its efficacy may be compromised by delayed parasitological responses.